Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-08-06

Clinical Trial Update: An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Ivacaftor in cystic fibrosis patients with two splicing mutations has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ivacaftor (ivacaftor)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2018-08-06